Skip to main content

Table 2 Patients’ characteristics at the time of first recurrence prior to CRT plus durvalumab (n = 24)

From: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

  Mean Range
Median disease-free intervala (months) 31.29 3–185
  Frequency %
Histological confirmation 13 54.2
Time to recurrence Frequency %
 < 1 year 10 41.7
 > 1 year 14 58.3
Pulmonary recurrence site Frequency %
 No pulmonary site 16 66.6
 At surgical staple lines 4 16.7
 Other lung sites 4 16.7
Lymph nodes relapse Frequency %
 Ipsilateral hilum 2 8.3
 Ipsilateral ilo-mediastinic 18 75.0
 Contralateral ilo-mediastinic 3 12.5
 Supraclavicular 1 4.2
PD-L1 expression Frequency %
 Negative 1 4.2
 ≤ 50% 11 45.9
 > 50% 12 50.0
PD-L1 assessment Frequency %
 At surgery 12 50.0
 At recurrence 12 50.0
ECOG performance status Frequency %
 0 15 62.5
 1 8 33.3
 2 1 4.2
  1. aFrom primary resection to recurrent disease diagnosis